Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Dexamethasone
Ozurdex
Routinely available
SMC (1046/15)
29/03/2023
Indication
Treatment of adult patients with visual impairment due to diabetic macular oedema who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.
Therapeutic Area
Eye
Status Description
Routinely available in line with national guidance
Formulation
700 micrograms intravitreal implant in applicator
Comments
-